Dainippon Pharmaceut (DNPUF) 10.4000 $DNPUF
Streptococcus Pyogenes Infections Pipeline Review, H2 2015 - 6 Companies & 10 Drug Profiles
M2 - Mon Oct 05, 8:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pxmsnq/streptococcus) has announced the addition of the "Streptococcus Pyogenes Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Streptococcus Pyogenes Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Streptococcus Pyogenes Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Absynth Biologics Limited - Aureogen Biosciences, Inc. - GlaxoSmithKline Plc - Helix BioMedix, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Wellstat Vaccines, LLC Drug Profiles - BMY-28117 - HB-1345 - SM-295291 - SM-369926 - Small Molecules to Inhibit DHFR for Infectious Diseases - Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections - streptococcus [serotype A] vaccine - streptococcus polysaccharide [serotype A] vaccine - streptococcus pyogenes vaccine - streptococcus pyogenes vaccine (30-valent) For more information visit http://www.researchandmarkets.com/research/px...eptococcus
GSK: 40.22 (+0.06)
Global Neisseria Gonorrhoeae Infections Pipeline Review 2015 - 10 Companies & 16 Drug Profiles
M2 - Mon Oct 05, 8:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vp26fv/neisseria) has announced the addition of the "Neisseria Gonorrhoeae Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Neisseria Gonorrhoeae Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neisseria Gonorrhoeae Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adenium Biotech ApS - Allergan Plc - BioDiem Ltd - Biolytics Pharma - Debiopharm International S.A. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Sarepta Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Vertex Pharmaceuticals Incorporated Drug Profiles - Antisense Oligonucleotide for Drug Resistant Neisseria Gonorrhoeae Infections - Arenicin - BDM-I - Biologic for Neisseria Gonorrhoeae Infection - Cribrostatin-6 - dalbavancin - Debio-1453 - gepotidacin mesylate - gonorrhoeae vaccine - SM-295291 - SM-369926 - Small Molecule to Inhibit Tubulin for Oncology and Neisseria Gonorrhoeae Infections - Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Small Molecules to Inhibit PBP2 for Neisseria Gonorrhoeae Infections - VT-12008911 - zoliflodacin For more information visit http://www.researchandmarkets.com/research/vp26fv/neisseria
AGN: 274.84 (-1.32), VRTX: 110.00 (+0.97), SRPT: 37.09 (-0.72), GSK: 40.22 (+0.06)
Fibrosarcoma Pipeline Review, H2 2015 - 6 Companies & 9 Drug Profiles
M2 - Wed Sep 23, 3:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j2h4np/fibrosarcoma) has announced the addition of the "Fibrosarcoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Fibrosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibrosarcoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advanced Proteome Therapeutics Corporation - Novartis AG - Plexxikon Inc. - Rigontec GmbH - Siena Biotech S.p.A. - Sumitomo Dainippon Pharma Co., Ltd. Drug Profiles - APC-103 - DSR-6434 - everolimus - ImOl-100 - KRA-0008 - LK-3 - MAT-303 - PLX-7486 - SEN-461 For more information visit http://www.researchandmarkets.com/research/j2...brosarcoma
NVS: 91.90 (-0.71)
Global Autism Pipeline Review, H2 2015 - 19 Companies & 31 Drug Profiles
M2 - Wed Sep 23, 3:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tf7gbm/autism_pipeline) has announced the addition of the "Autism - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - BioCrea GmbH - BrainStorm Cell Therapeutics Inc. - Cellceutix Corporation - Confluence Pharmaceuticals LLC - Curemark, LLC - Egenix, Inc. - F. Hoffmann-La Roche Ltd. - Heptares Therapeutics Limited - Intra-Cellular Therapies, Inc. - MedDay - Merz Pharma GmbH & Co. KgaA - Mnemosyne Pharmaceuticals, Inc. - Omeros Corporation - Otsuka Holdings Co., Ltd. - Retrophin Inc. - Reviva Pharmaceuticals Inc. - Saniona AB - Sumitomo Dainippon Pharma Co., Ltd. Drug Profiles - (dextromethorphan hydrobromide quinidine sulfate) - acamprosate calcium - ADX-71441 - ADX-88178 - aripiprazole - carbetocin - CM-AT - CN-2097 - Drug for Autism - HTL-14242 - ITI-007 - KM-391 - lurasidone hydrochloride - MD-1103 - memantine hydrochloride - oxytocin - RG-7314 - RO-5285119 - RP-5063 - Small Molecule to Agonize GABAA Receptor Subunit Alpha-5 for Autism - Small Molecule to Modulate GABRA5 Receptor for CNS Disorders - Small Molecule to Target GPR63 for Autism - Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism - Small Molecules to Antagonize NMDA2A for Central Nervous System Disorders - Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome - Small Molecules to Inhibit Translation Initiation Factor-4E for Cancer and Autism - Small Molecules to Target Oxytocin for Autism and Anxiety Disorders - Stem Cell Therapy for Multiple Sclerosis, Rheumatoid Arthritis, Autism and Bronchopulmonary Dysplasia - Stem Cell Therapy for Neurodegenerative Disorders - suramin hexasodium - VU-0410120 For more information visit http://www.researchandmarkets.com/research/tf...m_pipeline
RTRX: 20.22 (+1.07), ITCI: 43.85 (+1.72), BCLI: 2.87 (+0.13), OMER: 12.66 (+0.58)
Global Sarcopenia Pipeline Review, H2 2015 - 8 Companies & 14 Drug Profiles
M2 - Wed Sep 23, 2:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pm4ld2/sarcopenia) has announced the addition of the "Sarcopenia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sarcopenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sarcopenia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - GlaxoSmithKline Plc - Myos Corporation - Neurotune AG - Novartis AG - PolyNovo Limited - PsiOxus Therapeutics Limited - Regeneron Pharmaceuticals, Inc. - Sumitomo Dainippon Pharma Co., Ltd. Drug Profiles - AOD-9604 - ARM-210 - bimagrumab - BIO-101 - BIO-103 - Espindolol - NEP-28 - NT-1654 - Proteins for Musculoskeletal Disorders - Recombinant Protein for Sarcopenia - S-107 - Small Molecules to Inhibit Furin for Sarcopenia and Cachexia - Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis, Sarcopenia and Cachexia - trevogrumab For more information visit http://www.researchandmarkets.com/research/pm4ld2/sarcopenia
GSK: 40.22 (+0.06), REGN: 503.92 (+12.71), NVS: 91.90 (-0.71)
Nocturia Pipeline Review, H2 2015 - 4 Companies & 6 Drug Profiles
M2 - Wed Sep 23, 2:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4xhht7/nocturia) has announced the addition of the "Nocturia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Nocturia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nocturia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Allergan, Inc. - Ferring International Center S.A. - Sumitomo Dainippon Pharma Co., Ltd. - Vantia Therapeutics Drug Profiles - afacifenacin - ASP-7035 - desmopressin acetate - FE-999309 - fedovapagon - Paxerol For more information visit http://www.researchandmarkets.com/research/4xhht7/nocturia
AGN: 274.84 (-1.32)
Global Constipation Pipeline Review 2015 - 16 Companies & 18 Drug Profiles
M2 - Tue Sep 08, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b5h9s9/constipation) has announced the addition of the "Constipation - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Constipation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Constipation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlbireoPharma - Ardelyx, Inc. - Astellas Pharma Inc. - Braintree Laboratories, Inc. - Daiichi Sankyo Company, Limited - Dong-A Socio Group - Ironwood Pharmaceuticals, Inc. - Kissei Pharmaceutical Co., Ltd. - RaQualia Pharma Inc. - Rhythm Pharmaceuticals - Sanwa Kagaku Kenkyusho Co., Ltd. - Shire Plc - SK Biopharmaceuticals Co., Ltd. - Sucampo Pharmaceuticals, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Synergy Pharmaceuticals, Inc. Drug Profiles - ASP-7663 - BLI-400 - DA-6886 - DS-3801 - DSP-6952 - elobixibat - KWA-0711 - linaclotide - lubiprostone - plecanatide - prucalopride succinate - relamorelin - relenopride hydrochloride - RQ-00000010 - SK-1202 - Small Molecule to Activate 5-HT1 Receptor for Constipation and Dyspepsia - tenapanor hydrochloride - Transilon For more information visit http://www.researchandmarkets.com/research/b5...nstipation
SGYP: 6.32 (+0.18), IRWD: 11.36 (+0.24), SHPG: 200.90 (-1.85), SCMP: 18.19 (-1.21)
Streptococcus Pyogenes Infections Pipeline Review, H2 2015 - 6 Companies & 10 Drug Profiles
M2 - Mon Oct 05, 8:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pxmsnq/streptococcus) has announced the addition of the "Streptococcus Pyogenes Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Streptococcus Pyogenes Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Streptococcus Pyogenes Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Absynth Biologics Limited - Aureogen Biosciences, Inc. - GlaxoSmithKline Plc - Helix BioMedix, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Wellstat Vaccines, LLC Drug Profiles - BMY-28117 - HB-1345 - SM-295291 - SM-369926 - Small Molecules to Inhibit DHFR for Infectious Diseases - Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections - streptococcus [serotype A] vaccine - streptococcus polysaccharide [serotype A] vaccine - streptococcus pyogenes vaccine - streptococcus pyogenes vaccine (30-valent) For more information visit http://www.researchandmarkets.com/research/px...eptococcus
GSK: 40.22 (+0.06)
Global Neisseria Gonorrhoeae Infections Pipeline Review 2015 - 10 Companies & 16 Drug Profiles
M2 - Mon Oct 05, 8:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vp26fv/neisseria) has announced the addition of the "Neisseria Gonorrhoeae Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Neisseria Gonorrhoeae Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neisseria Gonorrhoeae Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adenium Biotech ApS - Allergan Plc - BioDiem Ltd - Biolytics Pharma - Debiopharm International S.A. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Sarepta Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Vertex Pharmaceuticals Incorporated Drug Profiles - Antisense Oligonucleotide for Drug Resistant Neisseria Gonorrhoeae Infections - Arenicin - BDM-I - Biologic for Neisseria Gonorrhoeae Infection - Cribrostatin-6 - dalbavancin - Debio-1453 - gepotidacin mesylate - gonorrhoeae vaccine - SM-295291 - SM-369926 - Small Molecule to Inhibit Tubulin for Oncology and Neisseria Gonorrhoeae Infections - Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Small Molecules to Inhibit PBP2 for Neisseria Gonorrhoeae Infections - VT-12008911 - zoliflodacin For more information visit http://www.researchandmarkets.com/research/vp26fv/neisseria
AGN: 274.84 (-1.32), VRTX: 110.00 (+0.97), SRPT: 37.09 (-0.72), GSK: 40.22 (+0.06)
Fibrosarcoma Pipeline Review, H2 2015 - 6 Companies & 9 Drug Profiles
M2 - Wed Sep 23, 3:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j2h4np/fibrosarcoma) has announced the addition of the "Fibrosarcoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Fibrosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibrosarcoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advanced Proteome Therapeutics Corporation - Novartis AG - Plexxikon Inc. - Rigontec GmbH - Siena Biotech S.p.A. - Sumitomo Dainippon Pharma Co., Ltd. Drug Profiles - APC-103 - DSR-6434 - everolimus - ImOl-100 - KRA-0008 - LK-3 - MAT-303 - PLX-7486 - SEN-461 For more information visit http://www.researchandmarkets.com/research/j2...brosarcoma
NVS: 91.90 (-0.71)
Global Autism Pipeline Review, H2 2015 - 19 Companies & 31 Drug Profiles
M2 - Wed Sep 23, 3:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tf7gbm/autism_pipeline) has announced the addition of the "Autism - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - BioCrea GmbH - BrainStorm Cell Therapeutics Inc. - Cellceutix Corporation - Confluence Pharmaceuticals LLC - Curemark, LLC - Egenix, Inc. - F. Hoffmann-La Roche Ltd. - Heptares Therapeutics Limited - Intra-Cellular Therapies, Inc. - MedDay - Merz Pharma GmbH & Co. KgaA - Mnemosyne Pharmaceuticals, Inc. - Omeros Corporation - Otsuka Holdings Co., Ltd. - Retrophin Inc. - Reviva Pharmaceuticals Inc. - Saniona AB - Sumitomo Dainippon Pharma Co., Ltd. Drug Profiles - (dextromethorphan hydrobromide quinidine sulfate) - acamprosate calcium - ADX-71441 - ADX-88178 - aripiprazole - carbetocin - CM-AT - CN-2097 - Drug for Autism - HTL-14242 - ITI-007 - KM-391 - lurasidone hydrochloride - MD-1103 - memantine hydrochloride - oxytocin - RG-7314 - RO-5285119 - RP-5063 - Small Molecule to Agonize GABAA Receptor Subunit Alpha-5 for Autism - Small Molecule to Modulate GABRA5 Receptor for CNS Disorders - Small Molecule to Target GPR63 for Autism - Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism - Small Molecules to Antagonize NMDA2A for Central Nervous System Disorders - Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome - Small Molecules to Inhibit Translation Initiation Factor-4E for Cancer and Autism - Small Molecules to Target Oxytocin for Autism and Anxiety Disorders - Stem Cell Therapy for Multiple Sclerosis, Rheumatoid Arthritis, Autism and Bronchopulmonary Dysplasia - Stem Cell Therapy for Neurodegenerative Disorders - suramin hexasodium - VU-0410120 For more information visit http://www.researchandmarkets.com/research/tf...m_pipeline
RTRX: 20.22 (+1.07), ITCI: 43.85 (+1.72), BCLI: 2.87 (+0.13), OMER: 12.66 (+0.58)
Global Sarcopenia Pipeline Review, H2 2015 - 8 Companies & 14 Drug Profiles
M2 - Wed Sep 23, 2:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pm4ld2/sarcopenia) has announced the addition of the "Sarcopenia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sarcopenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sarcopenia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - GlaxoSmithKline Plc - Myos Corporation - Neurotune AG - Novartis AG - PolyNovo Limited - PsiOxus Therapeutics Limited - Regeneron Pharmaceuticals, Inc. - Sumitomo Dainippon Pharma Co., Ltd. Drug Profiles - AOD-9604 - ARM-210 - bimagrumab - BIO-101 - BIO-103 - Espindolol - NEP-28 - NT-1654 - Proteins for Musculoskeletal Disorders - Recombinant Protein for Sarcopenia - S-107 - Small Molecules to Inhibit Furin for Sarcopenia and Cachexia - Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis, Sarcopenia and Cachexia - trevogrumab For more information visit http://www.researchandmarkets.com/research/pm4ld2/sarcopenia
GSK: 40.22 (+0.06), REGN: 503.92 (+12.71), NVS: 91.90 (-0.71)
Nocturia Pipeline Review, H2 2015 - 4 Companies & 6 Drug Profiles
M2 - Wed Sep 23, 2:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4xhht7/nocturia) has announced the addition of the "Nocturia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Nocturia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nocturia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Allergan, Inc. - Ferring International Center S.A. - Sumitomo Dainippon Pharma Co., Ltd. - Vantia Therapeutics Drug Profiles - afacifenacin - ASP-7035 - desmopressin acetate - FE-999309 - fedovapagon - Paxerol For more information visit http://www.researchandmarkets.com/research/4xhht7/nocturia
AGN: 274.84 (-1.32)
Global Constipation Pipeline Review 2015 - 16 Companies & 18 Drug Profiles
M2 - Tue Sep 08, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b5h9s9/constipation) has announced the addition of the "Constipation - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Constipation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Constipation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlbireoPharma - Ardelyx, Inc. - Astellas Pharma Inc. - Braintree Laboratories, Inc. - Daiichi Sankyo Company, Limited - Dong-A Socio Group - Ironwood Pharmaceuticals, Inc. - Kissei Pharmaceutical Co., Ltd. - RaQualia Pharma Inc. - Rhythm Pharmaceuticals - Sanwa Kagaku Kenkyusho Co., Ltd. - Shire Plc - SK Biopharmaceuticals Co., Ltd. - Sucampo Pharmaceuticals, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Synergy Pharmaceuticals, Inc. Drug Profiles - ASP-7663 - BLI-400 - DA-6886 - DS-3801 - DSP-6952 - elobixibat - KWA-0711 - linaclotide - lubiprostone - plecanatide - prucalopride succinate - relamorelin - relenopride hydrochloride - RQ-00000010 - SK-1202 - Small Molecule to Activate 5-HT1 Receptor for Constipation and Dyspepsia - tenapanor hydrochloride - Transilon For more information visit http://www.researchandmarkets.com/research/b5...nstipation
SGYP: 6.32 (+0.18), IRWD: 11.36 (+0.24), SHPG: 200.90 (-1.85), SCMP: 18.19 (-1.21)
